Thank you for pointing this out! It also seemed a bit low to me .. but I assumed that subsidies are never taken into account , although can be discussed as an opportunity (for example, for HPV “Gavi-subsidized [HPV] vaccine costs only US$0.20 to US$0.40 per dose, while program costs range between US$4 and US$13 per fully immunized girl (Denny and others 2015; Gavi 2013)” (vol. 3, p. 10).
But you are right—for pneumococcus GAVI seems to be using something like a sliding price scheme: “Rotavirus and pneumococcus vaccine costs to LICs are a fraction (for example, 5 percent) of the price paid by Gavi, the Vaccine Alliance to procure the vaccines; Gavi, in turn, receives prices that are more favorable than what upper-middle-income countries pay as a result of volume discounts and other factors” vol. 2, p. 15).
The cost in conflict zones or post-conflict areas does not need to be so high—for example, a high pay for a primary healthcare NGO employee in communities in Ambazonia controlled by armed groups can be $450/month. Another example is paying local community members in this region below the minimum wage ($0.25/hour) to share healthcare messages on COVID prevention (trekking to communities). Considering that vaccination requires little specialized training then the distribution cost could be low. Also, according to the primary healthcare NGO, the government clinics are closed due to the conflict, so after the organization stopped operating the mobile clinics, there was no primary healthcare for the communities. So, I hypothesize that some not easy, but cost-effective to reach patients are uncovered due to neglectedness. The majority of the internally displaced persons that the NGO served were extremely poor.
According to this study, a dose averts 0.059-0.067 DALYs (p. 12). So, for the cost to be $1/DALY, the provision of 1,000 vaccines would have to cost $59-$67, which requires low or no cost of the vaccine.
The argument for considering the subsidized price rather than the production cost is that philanthropes use marginal cost to others’ donations (that is done for deworming for which drugs are 100% donated). If the donation recommendation is for drug donors, such as pharmaceutical companies, then production cost (alongside with distribution and other expenses) should be taken into account to maximize cost-effectiveness.
Thank you for pointing this out! It also seemed a bit low to me .. but I assumed that subsidies are never taken into account , although can be discussed as an opportunity (for example, for HPV “Gavi-subsidized [HPV] vaccine costs only US$0.20 to US$0.40 per dose, while program costs range between US$4 and US$13 per fully immunized girl (Denny and others 2015; Gavi 2013)” (vol. 3, p. 10).
But you are right—for pneumococcus GAVI seems to be using something like a sliding price scheme: “Rotavirus and pneumococcus vaccine costs to LICs are a fraction (for example, 5 percent) of the price paid by Gavi, the Vaccine Alliance to procure the vaccines; Gavi, in turn, receives prices that are more favorable than what upper-middle-income countries pay as a result of volume discounts and other factors” vol. 2, p. 15).
The cost in conflict zones or post-conflict areas does not need to be so high—for example, a high pay for a primary healthcare NGO employee in communities in Ambazonia controlled by armed groups can be $450/month. Another example is paying local community members in this region below the minimum wage ($0.25/hour) to share healthcare messages on COVID prevention (trekking to communities). Considering that vaccination requires little specialized training then the distribution cost could be low. Also, according to the primary healthcare NGO, the government clinics are closed due to the conflict, so after the organization stopped operating the mobile clinics, there was no primary healthcare for the communities. So, I hypothesize that some not easy, but cost-effective to reach patients are uncovered due to neglectedness. The majority of the internally displaced persons that the NGO served were extremely poor.
According to this study, a dose averts 0.059-0.067 DALYs (p. 12). So, for the cost to be $1/DALY, the provision of 1,000 vaccines would have to cost $59-$67, which requires low or no cost of the vaccine.
The argument for considering the subsidized price rather than the production cost is that philanthropes use marginal cost to others’ donations (that is done for deworming for which drugs are 100% donated). If the donation recommendation is for drug donors, such as pharmaceutical companies, then production cost (alongside with distribution and other expenses) should be taken into account to maximize cost-effectiveness.